Navigation Links
Cardiome Discloses Chairman And CEO's Involuntary Share Sale
Date:11/28/2008

NASDAQ: CRME TSX: COM

VANCOUVER, Nov. 28 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today disclosed that its Chairman and Chief Executive Officer, Bob Rieder, was recently subject to involuntary margin sales of 45,000 common shares from his direct holding of Cardiome stock.

Mr. Rieder commented, "I am very disappointed to have been required to involuntarily sell any shares of Cardiome, particularly at such an inopportune time; however the global financial crisis and associated market decline has had a profound impact on all stocks including our own. Since joining Cardiome as CEO in 1998, I have always practiced my belief that the leader of a company should have a direct and material financial stake in the company's success, and I have consistently held a substantial proportion of my personal assets in Cardiome shares. My faith and confidence in Cardiome's success is absolutely undiminished as we drive the company forward to the exciting times that lie ahead."

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "i
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Cardiome Provides Regulatory Update
2. Cardiome To Release Second Quarter Results And Hold Conference Call
3. Cardiome Announces Preferred Share Financing
4. Cardiome Announces Positive Phase 2b Results For Oral Vernakalant
5. Cardiome To Hold Conference Call
6. Cardiome Reports First Quarter Results
7. Cardiome To Release 2008 First Quarter Results
8. Cardiome To Release 2007 Results
9. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
10. Cardiome And Astellas Announce Regulatory Update
11. Cardiome to Hold Investor Update Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... (PRWEB) May 18, 2013 Although obesity ... tumors, the association between obesity and esophageal adenocarcinoma, a ... other obesity-related tumors. As reported on Cancer.gov, ... are almost twice as likely as those of normal ... the relationship between obesity and esophageal cancer is not ...
(Date:5/18/2013)... “Sleep Apnea Diagnostic & Therapeutic Devices Market [Polysomnographs, Respiratory ... Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, Competitive Landscape ... market drivers, restraints, and opportunities in North America, Europe, ... 147 market data tables ... 318 pagesand in-depth TOC of “Sleep Apnea Diagnostic ...
(Date:5/18/2013)... Florida (PRWEB) May 18, 2013 Adolescents, ... also known as “Spice” or “K2” are landing in ... helping to curb this drug epidemic with a ... synthetic marijuana. , According to research from the National ... second-most popular illegal drug among American teenagers. In 2012, ...
(Date:5/18/2013)... DF (PRWEB) May 18, 2013 The ... leading ayurvedic education institution in the West. Program is ... education. , Ayurveda is a healing modality practiced for ... ), it is considered that health begins when an ... profound understanding of their individual needs. Ayurveda aims to ...
(Date:5/18/2013)... Bay, CA (PRWEB) May 18, 2013 ... , has recently completed a stylish renovation that features ... advanced specialties. , From the ground up, this ... improved with fresh flooring, soothing colors and comfortable spa ... been installed, including an Apilus epilator machine. The ...
Breaking Medicine News(10 mins):Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:Rio Salon and Spa, a Beauty Salon in Morro Bay, Undergoes Makeover 2
... new study shows that Multidetector CT (MDCT) without the use of ... This helps in avoiding the need for surgeons to do ... ,In the past, the best way to find ... contrast media then watch to see if and where the contrast ...
... Previous studies have suggested that drinking a lot of coffee ... result in miscarriage or premature delivery. ,A recent ... of a link between caffeine intake and pregnancy outcome. ... 1,000 women in the initial stages of pregnancy who drank ...
... licenses for inexpensive versions of heart disease and AIDS ... pharmaceutical bigwigs. Health Minister, Mongkol Songkhla, confirmed that the ... ,According to the Health Minister, the drugs are meant ... elaborate on whether the drugs would be generic substitutes ...
... have discovered that learning appears to slow the development of ... The finding suggests that the elderly, by keeping their minds ... The study appears in the Jan. 24 issue of the ... modified mice is the first to show that short but ...
... of the mineral selenium appear to reduce or slow ... selenium have been noted in HIV-positive patients, and evidence ... system function, the researchers report in the Jan. 22 ... ,"Those individuals who were treated with selenium displayed ...
... equally effective alternative therapy for controlling hot flushes and ... derived from progesterone may be as effective as estrogen ... synthetic version of the hormone progesterone, was first made ... available in an oral form – said Dr.Jerilynn Prior, ...
Cached Medicine News:Health News:Learning Slows Physical Progression of Alzheimer's Disease: Study 2Health News:Selenium Supplements May Slow Progression of HIV: Report 2Health News:Selenium Supplements May Slow Progression of HIV: Report 3
(Date:5/16/2013)... 2013  PTC Therapeutics, Inc., today announced that it ... the U.S. Securities and Exchange Commission ("SEC") relating to ... The number of shares to be offered and the ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... book-running managers for the offering. Cowen and Company is ...
(Date:5/16/2013)... Mass. and SYDNEY , May ... - ASX: HIN), a leading innovator of less invasive, ... advanced heart failure, today announced that CEO Doug ... UBS Global Healthcare Conference at 11:00 a.m. EDT on Monday, ... 2013 at the Sheraton New York Hotel. A ...
(Date:5/16/2013)... CITY, Calif. , May 16, 2013 AcelRx ... company focused on the development and commercialization of innovative therapies ... that Richard King , President and CEO, ... Conference at the Sheraton New York Hotel in ... Wednesday, May 22, 2013 at 9:30 a.m. ET/6:30 a.m. PT. ...
Breaking Medicine Technology:PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 3
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), ... associated with inflammation, today announced that their product candidate ... Research Award at the Third Congress of the European ... Dr. Daniele De Luca, MD, PhDst at the University ...
... Dec. 7, 2010 InfraReDx, Inc. ... imaging technologies, today announced the publication of a case ... stent thrombosis with lipid core plaque as detected by ... first and only FDA-approved system to provide a Chemogram™ ...
Cached Medicine Technology:Varespladib Receives 2010 European Society Pediatric Research Award 2Varespladib Receives 2010 European Society Pediatric Research Award 3InfraReDx Announces Publication of a Case Report in Circulation Highlighting Novel Clinical Finding with LipiScan™ Coronary Imaging System 2
... red blood cell (nRBC) control for evaluating the ... 755 hematology analyzer in its enumeration of the ... LH 750/LH 755. nRBC-Chex for LH is a ... for LH has a 75-day closed-vial stability and ...
... negative whole blood control to test for ... tests and hemoglobin electrophoresis. Sickle-Chex is compatible ... solubility kits. Sickle-Chex is packaged in a ... dispenses an accurate sample volume. No pipeting ...
... EX.P.R.T. Release Technology essentially eliminates premature ... Unique anatomically designed tapered stent for ... 0.014 Rapid Exchange catheter with 6 ... atraumatic tip,, Radiopaque marker on catheter ...
... is a three-part differential control assayed for all ... Series, T Series, AcT/AcT diff/AcT diff2, MD Series ... 1700, and 1800; ABX Micros 60; and Diatron ... an open-vial stability of 30 days and a ...
Medicine Products: